A comparison of telbivudine and entecavir for chronic hepatitis B in real-world clinical practice

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 3, 2012, Pages 696-699

  Tsai, Ming Chao ^a   Lee, Chuan Mo ^a   Chiu, King Wah ^a   Hung, Chao Hung ^a   Tung, Wei Chih ^a   Chen, Chien Hung ^a   Tseng, Po Lin ^a   Chang, Kuo Chin ^a   Wang, Jing Houng ^a   Lu, Sheng Nan ^a   Yen, Yi Hao ^a   Hu, Tsung Hui ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

HBeAg seroconversion; HBV; Roadmap

Indexed keywords

ALANINE AMINOTRANSFERASE; ENTECAVIR; HEPATITIS B(E) ANTIGEN; TELBIVUDINE; VIRUS DNA;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL RESISTANCE; ARTICLE; CHRONIC HEPATITIS; CLINICAL PRACTICE; COMPARATIVE STUDY; CONTROLLED STUDY; DNA DETERMINATION; DRUG EFFICACY; FEMALE; FOLLOW UP; HEPATITIS B; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PROBABILITY; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS DETECTION;

ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; GUANINE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MALE; MIDDLE AGED; NUCLEOSIDES; PYRIMIDINONES; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84863011075     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr495     Document Type: Article

References (10)

1. Iloeje UH, Yang HI, Su J et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 678-86.
2. Keeffe EB, Zeuzem S, Koff RS et al. Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol 2007; 5: 890-7.
3. Lai CL, Gane E, Liaw YF et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007; 357: 2576-88.
4. Liaw YF, Gane E, Leung N et al. 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009; 136: 486-95.
5. Liaw YF, Chu CM. Hepatitis B virus infection. Lancet 2009; 373: 582-92.
6. Zeuzem S, Gane E, Liaw YF et al. Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B. J Hepatol 2009; 51: 11-20.
7. Chang TT, Gish RG, de Man R et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354: 1001-10.
8. Chen CH, Lee CM, Lu SN et al. Comparison of sequence changes of precore and core promoter regions in HBeAg-positive chronic hepatitis B patients with and without HBeAg clearance in lamivudine therapy. J Hepatol 2006; 44: 76-82.
9. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-2.
10. Liaw YF. Hepatitis flares and hepatitis B e antigen seroconversion: implication in anti-hepatitis B virus therapy. J Gastroenterol Hepatol 2003; 18: 246-52.